Today's Pharma Pulse
Ona lands $86.6M Series B, one of Spain’s biggest biotech financings
Spanish biotech Ona announced a $86.6 million Series B round, ranking among the largest venture financings in Spain’s life‑science sector this year. The round was led by Seventure Partners with participation from existing backers and new strategic investors. The funds will expand Ona’s AI‑driven drug discovery platform and accelerate its pre‑clinical pipeline.
Check Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers
The article outlines the legal requirement that U.S. wholesale drug distributors and third‑party logistics providers (3PLs) must hold a valid state license to handle prescription medications. It warns that unlicensed or unauthorized partners can expose patients to counterfeit, stolen, or diverted drugs. To ensure compliance, businesses should consult each state’s licensing portal and the FDA’s annual reporting database to confirm a partner’s status. A comprehensive table lists the responsible licensing agency for every state, serving as a practical reference for verification.
Medochemie's Green Energy Transition Signals New Era for Pharmaceutical Manufacturing
Medochemie, Cyprus’s largest generic drug maker, has powered all nine of its GMP‑certified manufacturing sites with 100% renewable electricity as of 1 October 2025, covering roughly 18 million kWh annually and eliminating thousands of tonnes of CO₂. The transition aligns the firm with tightening...
J&J Wins Third National Priority Approval for Multiple Myeloma Combo
Johnson & Johnson’s Tecvayli and Darzalex combination received FDA approval for second‑line multiple myeloma treatment, marking the third drug cleared under the Commissioner’s National Priority Voucher (CNPV) program. The decision was rendered in just 55 days after J&J’s filing, thanks...
Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection
The FDA has issued a draft Level 1 guidance (Docket FDA‑2025‑D‑1504) titled “Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection.” The document targets both foreign and domestic manufacturers of human and animal drugs regulated by CDER,...
From MFN to IRA, Experts Warn of a System Under Pressure in Wide-Ranging Policy Webinar
The March 3, 2026 AJMC/MHE webinar examined the Trump administration’s Great Healthcare Plan, focusing on most‑favored‑nation (MFN) drug pricing, the lapse of ACA marketplace subsidies, and the Inflation Reduction Act’s (IRA) impact on community oncology. Sixteen manufacturers have voluntarily adopted MFN pricing,...
Biopharma’s Recent String of CEO Splits
Three biopharma firms—Bavarian Nordic, Sarepta Therapeutics, and Alkermes—announced the departures of long‑standing CEOs, prompting short‑term share declines. Bavarian Nordic’s Paul Chaplin steps down after a blocked $3 billion buyout, while Sarepta’s Doug Ingram leaves amid family health issues and recent product...
BBC Infographic Explains UniQure Gene Therapy for Huntington
Especially after the recent disappointing regulatory update regarding $QURE AMT-130 clinical candidate for treating Huntington disease and the FDA refusal to move forward 🧵👇- here is an excellent Infograph by the BBC which explains how exactly the mechanism of @uniQure_NV’s...
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Immuneering Corporation announced its 2025 financial results, highlighting a 64% overall survival rate at 12 months for atebimetinib plus modified gemcitabine/nab‑paclitaxel in first‑line pancreatic cancer. The company secured FDA and EMA alignment on the design of its pivotal Phase 3 MAPKeeper 301...
TaiGen Completes Enrolment and Doses First Patient with Insilico Medicine’s ISM4808 in P-I Trial
Insilico Medicine and TaiGen announced that enrollment for the Phase‑I trial of ISM4808, an AI‑designed therapy for CKD‑related anemia, is now complete and the first patient has been dosed. The study comprises single‑ascending‑dose and multiple‑ascending‑dose cohorts evaluating safety and pharmacokinetics...
PE Eyes Growth Opportunities in Active Pharmaceutical Ingredients: 5 Deals
Private equity firms are actively pursuing growth in the active pharmaceutical ingredient (API) sector, with five recent transactions highlighted by Astorg, EQT, New Mountain Capital and TA Associates. The deals involve both acquisitions and divestitures of API manufacturing assets, reflecting...
Magnetic Nanoparticles Could Make Doxorubicin Delivery More Precise
Researchers have engineered a magnetic nanocarrier (IO@MBD) that combines γ‑Fe₂O₃ nanoparticles with a melamine‑based dendrimer to deliver doxorubicin. The platform achieves roughly 17 wt% drug loading, remains dispersible in water, and releases the drug preferentially under acidic conditions typical of tumor...
From Approval to Access: 4 Steps to Rethinking Market Access Strategy in Specialty Pharma
The article outlines a four‑step framework for specialty pharma companies to redesign market‑access strategies as they move from approval to commercial launch. It stresses securing payer formulary placement, deploying a focused sales force, establishing a trusted pharmacy network, and centering...
Pharma Pulse: Eli Lilly’s Employer Connect Platform and Tandem Mobi Android Integration
Eli Lilly has introduced Employer Connect, a new platform that partners with more than fifteen independent administrators to provide cost‑transparent access to its obesity drug Zepbound for U.S. employees. The service is designed to close the insurance coverage gap affecting roughly...
How the AI Shift Is Happening Now in Data Management
The latest generation of AI‑driven tools is transforming clinical trial data management by automating the build of electronic data capture (EDC) systems. Solutions such as CRScube’s AI‑led EDC builder can convert a PDF protocol into a structured database in hours...
Johnson & Johnson Reports the US FDA Approval of Tecvayli + Darzalex Faspro for R/R Multiple Myeloma
Johnson & Johnson announced FDA approval of the Tecvayli (teclistamab) and Darzalex Faspro (subcutaneous daratumumab with hyaluronidase) combination for adults with relapsed/refractory multiple myeloma who have received at least one prior line of therapy. The approval is grounded in the Phase III...
Seqster Unveils 1-Click DataLake for Clinical Trials
Seqster has introduced 1‑Click DataLake, a real‑world data platform that aggregates anonymized electronic health‑record information from over 150 million patients and 200,000 clinicians across the United States. The solution delivers real‑time, longitudinal patient journeys to speed trial design, feasibility assessments, and...
Liberate Bio Gains Licences for Myeloid-Specific CAR Design Patents
Liberate Bio announced it has secured both exclusive and non‑exclusive licenses for patents covering chimeric antigen receptor (CAR) designs specifically engineered for myeloid cells such as monocytes and macrophages. The patents, obtained from Carisma Therapeutics and the University of Pennsylvania,...
How the ‘Holy Grail’ Weight Loss Pill Became a Reality, and What Comes Next
The pharmaceutical industry has finally delivered an oral GLP‑1 weight‑loss pill, with Novo Nordisk launching an oral version of Wegovy earlier this year. Eli Lilly’s oral GLP‑1 candidate, orforglipron, is expected to receive approval imminently. Oral formulations overcome the injection barrier that...
Reversing Tumor Immunosuppression with Next-Gen GPCR Modulation
Kainova Therapeutics, formerly Domain Therapeutics, announced a Series B funding round to advance its next‑generation GPCR‑modulating platform aimed at reversing tumor immunosuppression. The rebrand signals a strategic shift toward a broader oncology focus, leveraging GPCR pathways that control immune cell trafficking....
Harrison.ai Secures the US FDA 510(k) Clearance for Acute Infarct Triage on Non-Contrast CT Brain
Harrison.ai has received U.S. FDA 510(k) clearance for its Acute Infarct Triage software, which analyzes non‑contrast CT brain scans to identify acute ischemic strokes. In validation studies the algorithm achieved roughly 89% sensitivity on thin‑slice CT and 86% on thicker...
Roche and Zealand Pharma Report P-II (ZUPREME-1) Trial Data on Petrelintide in Obesity
Roche and Zealand Pharma disclosed Phase‑II (ZUPREME‑1) results for petrelintide, an amylin‑analog injected weekly, in 493 overweight or obese adults (mean BMI 37 kg/m²) with weight‑related comorbidities. The trial evaluated five dose levels against placebo over 42 weeks and met its primary endpoint,...
Taming the AI Chaos in Drug Discovery
Biopharma R&D is witnessing a rapid influx of specialized AI models for tasks such as structure prediction, retrosynthesis, and image analysis. While each tool delivers measurable benefits, their isolated deployment creates fragmented data streams, hidden costs, and increased cognitive load...
Engineered Brain Cells Clear Dementia Plaques in Mice
Boosted Brain Cells Erase Dementia-Linked Proteins “At nearly six months of age, when untreated mice normally have brains saturated with harmful plaques, brains of treated mice were plaque-free. Meanwhile, older mice with plaque-saturated brains at the time of treatment saw a...
Servier's $2.5B DAWN Deal Closes Ojemda Saga
$DAWN acquisition by Servier for $2.5bn is quite the ending for Ojemda. Who remembers this RAF inhibitor's bizarre & convoluted history? $BIIB $TAK https://t.co/uD5drO9ymr
Combination GLP-1 Therapy Reduces Fat Mass While Preserving Lean Muscle in Adults with Obesity
A recent double‑blind trial found that a combination of two GLP‑1 receptor agonists cut fat mass significantly while sparing lean muscle in adults with obesity. Over 24 weeks, participants lost an average of 5 % body fat, with lean mass decline...
Offshoring Drug Discovery Could Create Massive US Trade Deficit
Jake puts it crisply: >If discovery and early development move abroad, the nation risks locking in a massive trade imbalance: Foreign countries develop the drugs, and Americans pay the bills.
Cranberry-Derived Ergostane Restores Ovarian Function in Mice
Ergostane steroid, as one of the major contributor to cranberry derived extracellular vesicle nanoparticles, restores ovarian function of murine premature ovarian failure https://t.co/CFcjDvzMnU https://t.co/le7VTHjEKa
Promising Henlus Data Tripped up by Psychedelic Trial Design Dilemma
Helus Pharma reported Phase II data for its psychedelic candidate HLP004, indicating symptom improvement in generalized anxiety disorder patients for up to six months. However, the trial’s low‑dose active control arm showed similar efficacy, making it difficult to isolate the...
Promising Helus Data Tripped up by Psychedelic Trial Design Dilemma
Helus Pharma reported Phase II data for its psychedelic candidate HLP004 in generalized anxiety disorder, showing symptom improvement lasting six months. However, the trial’s active low‑dose control produced outcomes similar to the therapeutic dose, making it difficult to isolate the drug’s...
Degenerating Tanycytes Disrupt Tau Removal, Shaping Alzheimer’s Progression
Researchers from Kyoto University and INSERM identified tanycytes as a previously unknown conduit that clears tau protein from cerebrospinal fluid into the bloodstream. In rodent and cellular models, blocking vesicular transport in these cells dramatically slowed tau efflux and worsened...
Advanced Vaccine Manufacturing in Australia to Supply Canada with 15 Million Pandemic Doses
Australian biotech firm CSL Seqirus has secured a contract with Canada’s Public Health Agency to deliver up to 15 million doses of a cell‑based, adjuvanted pandemic influenza vaccine if the WHO declares a pandemic. The doses will be manufactured at CSL...
UT San Antonio Awarded $38B ARPA-H Grant for Drug Trials
UT San Antonio has been given a $38biin ARPA-H grant to study the health benefit effects of three drugs in humans, namely, rapamycin, dapagliflozin and semaglutide …🧵 https://t.co/fAX14ngoyD
Ribosome-Targeted Drugs Redefine Psychiatry and Beyond
Ribosomes as Drug Targets. The Quiet Rewrite of Psychiatry and Beyond. | Ep. 950 https://t.co/gKlWpzO1Ci https://t.co/ImGOmUVrSO
![[Comment] Pimicotinib: A New Agent for an Orphan Disease](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/5b160e8a2b2821c82aa66047ca629679.webp)
[Comment] Pimicotinib: A New Agent for an Orphan Disease
Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive neoplasm driven by CSF‑1 over‑expression. The phase 3 MANEUVER trial evaluated pimicotinib, a selective CSF1R kinase inhibitor, against placebo in patients with inoperable or relapsed diffuse‑type TGCT. Results demonstrated statistically significant...
![[Correspondence] Changes in Paracetamol and Leucovorin Use After a White House Briefing](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/59b0c8a4048a3d105c9221755df21495.webp)
[Correspondence] Changes in Paracetamol and Leucovorin Use After a White House Briefing
The White House briefing on Sept 22 2025 linking prenatal acetaminophen to autism and promoting leucovorin was followed by an interrupted‑time‑series analysis of the Epic Cosmos database. Emergency‑department orders for paracetamol among pregnant women fell 10% (OER 0.90) while use among non‑pregnant women showed...
Asia Deals Aim for First-in-Class Biology, with at Least Four Deals for New Targets
Asian biotech firms outside China announced 72 deals in 2024‑25, emphasizing first‑in‑class assets over me‑better or me‑too programs. At least four transactions involve novel targets such as CNTN4, GPR52, MTARC1 and OK‑1, spanning new modalities and indications. Global pharmaceutical companies...
Your GLP-1 Drugs May Also Have Yet Another Undiscovered Benefit
A new observational study of nearly 22,000 chronic‑migraine patients found that those who started GLP‑1 receptor agonists for diabetes or obesity experienced fewer severe migraine events than peers on the preventive drug topiramide. Over a 12‑month follow‑up, GLP‑1 users had...
Consent‑Driven Targeting: Building Trust With Patients and HCPs
Life‑science marketers face mounting pressure to deliver personalized content while meeting stricter privacy regulations such as CCPA and the EU Data Act. Companies are shifting from static consent checkboxes to unified, real‑time consent frameworks that synchronize preferences across CRM, CDP,...
What Is Driving the Recent Wave of Layoffs in Biotech?
Biotech firms are cutting staff as venture‑capital inflows dry up, clinical‑trial setbacks mount, and operating costs climb. While breakthroughs in gene therapy, RNA therapeutics and precision medicine continue, companies are trimming non‑core programs to preserve cash. Strategic restructurings aim to...
FDA Issues RFI on In-Home Opioid Disposal Products
The FDA issued a Request for Information (RFI) on March 5, 2026, asking for public input about new standards for in‑home opioid disposal products. The agency is evaluating whether opioid manufacturers should be required to supply disposal systems directly through dispensers....
Gene Therapy Leaps: Base Editing, CAR‑astrocytes, iPSC Approval
stunning week in cell and gene therapy: in vivo base editing of PCSK9 delivered via LNP, w clinical data (Nat Med), preclinical POC of CAR-astrocytes engineered w AAV (Science) and of self-amplifying RNA delivered IM (also Science), Japan approves gene...
Therapeutic mRNA Reverses Genetic Infertility in Male Mouse Model
Scientists delivered naked Cldn11 messenger RNA directly into the testes of genetically infertile male mice, restoring Sertoli cell function and enabling spermatogenesis. The treatment produced viable sperm that generated healthy offspring via in‑vitro fertilization, without permanent germline alteration. The approach...
Activities Report of the Generic Drug Program (FY 2025) – FDARA Title VIII Sections 807 and 805
The FDA’s FY 2025 Generic Drug Program report details progress on abbreviated new drug applications (ANDAs) under priority review and competitive generic therapy (CGT) designations. By the fourth quarter, pending priority‑review ANDAs fell to 40, while CGT ANDAs awaiting FDA action...
L
Doesn’t look like $LLY and $NVO have much to worry about from $RHHBY obesity 🤷🏻♂️
Schrödinger Stock – A Dead Cat Bounce?
Schrödinger’s stock has plunged 88% over five years, leaving a sub‑$1 billion market cap. The company’s AI‑driven software segment posted 11% revenue growth in 2025 and aims for modest 12% growth in 2026, while shifting customers to cloud contracts that compress...
Patient-Focused Drug Development Glossary
The FDA released a comprehensive Patient‑Focused Drug Development (PFDD) glossary to standardize terminology across its guidance documents mandated by the 21st Century Cures Act and PDUFA VI. The glossary defines key concepts such as attributes, benefit‑risk assessment, clinical outcome assessments, patient‑reported...
Self‑amplifying RNA Could Protect Future Heart‑attack Patients
Will we give a shot of protective, self-amplifying RNA in patients with a heart attack in the future? @ScienceMagazine an intriguing innovation https://t.co/FcJme1ElyU https://t.co/lABFRkR3qg
Gül Dölen – Psychedelic Science and Radical Healing
Gül Dölen, a leading neuroscientist at UC Berkeley and Johns Hopkins, discussed the transformative potential of psychedelic‑assisted therapy during the 2025 Aspen Ideas Festival. Her research demonstrates that compounds such as psilocybin and MDMA can rapidly alleviate treatment‑resistant depression, complex PTSD,...
Pharmaceutical Executive Daily: Cognito Therapeutics and Nexcure Secure Financing Rounds
Cognito Therapeutics closed an oversubscribed $105 million Series C round to fast‑track its neurodegenerative programs, while Nexcure raised $19 million in a Series A to fund its immunology pipeline. At the same time, artificial‑intelligence advances—particularly large language models—are reshaping pharmacovigilance by automating analysis of...
Is Neurodegeneration a Systemic Metabolic Condition?
British biotech Vesalic reports a breakthrough that links amyotrophic lateral sclerosis (ALS) to a systemic metabolic dysfunction detectable in blood extracellular vesicles (EVs). The company says the EVs carry a toxic lipid cargo that harms motor neurons, and its blood‑based...